The UK femtech market sits within a global opportunity estimated at $25 billion, with fertility alone accounting for substantial demand: one in seven UK couples report conception difficulties, and IVF treatment numbers have risen nearly 60 percent [#112].
The real gap isn't market size. It's investment and evidence. Funding historically flowed elsewhere, though investor attitude shifted markedly between 2015 and 2019 [Ep 26]. The current constraint is twofold: awareness among VCs that femtech deserves capital allocation relative to its market opportunity [#253], and the foundational science problem. Much femtech in development lacks a rigorous evidence base because baseline knowledge of women's health conditions remains incomplete [#430]. That data gap creates both risk and opportunity. Early-stage companies capturing real-world evidence on menstrual cycles, menopause, pregnancy, and conditions affecting women differently than men could simultaneously fill a clinical void and build defensible products [#430]. The NHS itself reaches women too late in their health journey, meaning consumer-facing digital solutions face less institutional friction than in many other sectors. What's needed now is not market validation but VC education and founders willing to build on science they help establish.
Search 450+ episodes and 42,000 chunks of healthtech conversation.